881673-86-5

Basic information

• Product Name: Carbamic acid, methyl[[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methyl]-, 1,1-dimethylethyl ester
• CAS NO: 881673-86-5
• Molecular Formula: C23H26N2O4S
• Molecular Weight: 426.536
• Mol File: 881673-86-5.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, methyl[[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, methyl[[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methyl]-, 1,1-dimethylethyl ester(881673-86-5)
• EPA Substance Registry System: Carbamic acid, methyl[[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methyl]-, 1,1-dimethylethyl ester(881673-86-5)

Safety Data

• Hazardous Substances Data: 881673-86-5(Hazardous Substances Data)

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 16420-39-6 methyl 5-bromo-1H-pyrrole-3-carboxylate 
• 881673-83-2 1-[5-bromo-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine 
• 881673-82-1 5-bromo-1-(phenylsulfonyl)-1H-pyrrole-3-carbaldehyde 
• 881673-81-0 [5-bromo-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methanol 
• 881673-80-9 methyl 5-bromo-1-(phenylsulfonyl)-1H-pyrrole-3-carboxylate 
• 2703-17-5 methyl 1H-pyrrole-3-carboxylate 
• 881673-84-3 tert-butyl {[5-bromo-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-methyl}methylcarbamate 
• 144-55-8 sodium hydrogencarbonate 
• 98-80-6 phenylboronic acid 

Downstream Products

• 881678-78-0 N-methyl-1-[5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-methanamine hydrochloride 

Relevant articles and documents

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers

To discover a gastric antisecretory agent more potent than existing proton pump inhibitors, novel pyrrole derivatives were synthesized, and their H +,K+-ATPase inhibitory activities and inhibitory action on histamine-stimulated gastric acid secretion in rats were evaluated. Among the compounds synthesized, compound 17a exhibited selective and potent H +,K+-ATPase inhibitory activity through reversible and K+-competitive ionic binding; furthermore, compound 17c exhibited potent inhibitory action on histamine-stimulated gastric acid secretion in rats and Heidenhain pouch dogs.

PROTON PUMP INHIBITORS

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

PROTON PUMP INHIBITORS

Proton pump inhibitors which have excellent proton pumping activity and which can be converted in vivo into proton pump inhibitors to exhibit antiulcer effect and so on, containing compounds represented by the general formula (I) or salts thereof or prodrugs of the same: (I) wherein X and Y are each independently a free valency or a spacer whose main chain has 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, optionally substituted thienyl, optionally substituted benzo[b]thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrazolyl, optionally substituted pyrimidinyl, acyl, halogeno, cyano, or nitro; and R5 and R6 are each independently hydrogen or an optionally substituted hydrocarbon group.